Shots:
- Takeda & Innovent Biologics have entered into a global Partnership (Excluding Greater China) to develop & Commercialize IBI363 & IBI343; Takeda also Gains exclusive Option to license global rights for IBI3001 outside of Greater China
- As per the deal, Takeda will pay Innovent $1.2B upfront, including a $100M equity investment, funded from cash on hand. Innovent is also eligible for milestones, royalties, and a 40/60 US profit/loss split on IBI363
- Takeda will lead US co-commercialization and hold exclusive rights to commercialize IBI363 outside the US and Greater China, with global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the US. Takeda will also develop, manufacture, & commercialize IBI343 globally (excluding Greater China). If Takeda opts into IBI3001, additional fees and payments will apply
Ref: Takeda| Image: Innovent Biologics & Takeda| Press Release
Related News:- Nabla Bio Collaborates with Takeda to Advance AI-Driven Protein Therapeutics Design
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
